The forgotten lipids

Triglycerides, remnant cholesterol, and atherosclerotic cardiovascular disease risk

Pratik B. Sandesara, Salim S. Virani, Sergio Fazio, Michael Shapiro

    Research output: Contribution to journalReview article

    5 Citations (Scopus)

    Abstract

    Atherosclerotic cardiovascular disease (ASCVD) remains the leading cause of death worldwide. Low-density lipoprotein cholesterol (LDL-C) is a well-established mediator of atherosclerosis and a key target for intervention for the primary and secondary prevention of ASCVD. However, despite substantial reduction in LDL-C, patients continue to have recurrent ASCVD events. Hypertriglyceridemia may be an important contributor of this residual risk. Observational and genetic epidemiological data strongly support a causal role of triglycerides (TGs) and the cholesterol content within triglyceride-rich lipoproteins (TGRLs) and/or remnant cholesterol (RC) in the development of ASCVD. TGRLs are composed of hepatically derived very low-density lipoprotein and intestinally derived chylomicrons. RC is the cholesterol content of all TGRLs and plasma TGs serve as a surrogate measure of TGRLs and RC. Although lifestyle modification remains the cornerstone for management of hypertriglyceridemia, many novel drugs are in development and have shown impressive efficacy in lowering TG levels. Several ongoing, randomized controlled trials are underway to examine the impact of these novel agents on ASCVD outcomes. In this comprehensive review, we provide an overview of the biology, epidemiology, and genetics of TGs and ASCVD; we discuss current and novel TG-lowering therapies under development.

    Original languageEnglish (US)
    Pages (from-to)537-557
    Number of pages21
    JournalEndocrine reviews
    Volume40
    Issue number2
    DOIs
    StatePublished - Jan 1 2019

    Fingerprint

    Triglycerides
    Cardiovascular Diseases
    Cholesterol
    Lipids
    Lipoproteins
    Hypertriglyceridemia
    LDL Cholesterol
    Chylomicrons
    Molecular Epidemiology
    VLDL Lipoproteins
    Primary Prevention
    Secondary Prevention
    Life Style
    Cause of Death
    Atherosclerosis
    Randomized Controlled Trials
    Pharmaceutical Preparations

    ASJC Scopus subject areas

    • Endocrinology, Diabetes and Metabolism
    • Endocrinology

    Cite this

    The forgotten lipids : Triglycerides, remnant cholesterol, and atherosclerotic cardiovascular disease risk. / Sandesara, Pratik B.; Virani, Salim S.; Fazio, Sergio; Shapiro, Michael.

    In: Endocrine reviews, Vol. 40, No. 2, 01.01.2019, p. 537-557.

    Research output: Contribution to journalReview article

    @article{a1a41412d6244f91816f8cf6a3870883,
    title = "The forgotten lipids: Triglycerides, remnant cholesterol, and atherosclerotic cardiovascular disease risk",
    abstract = "Atherosclerotic cardiovascular disease (ASCVD) remains the leading cause of death worldwide. Low-density lipoprotein cholesterol (LDL-C) is a well-established mediator of atherosclerosis and a key target for intervention for the primary and secondary prevention of ASCVD. However, despite substantial reduction in LDL-C, patients continue to have recurrent ASCVD events. Hypertriglyceridemia may be an important contributor of this residual risk. Observational and genetic epidemiological data strongly support a causal role of triglycerides (TGs) and the cholesterol content within triglyceride-rich lipoproteins (TGRLs) and/or remnant cholesterol (RC) in the development of ASCVD. TGRLs are composed of hepatically derived very low-density lipoprotein and intestinally derived chylomicrons. RC is the cholesterol content of all TGRLs and plasma TGs serve as a surrogate measure of TGRLs and RC. Although lifestyle modification remains the cornerstone for management of hypertriglyceridemia, many novel drugs are in development and have shown impressive efficacy in lowering TG levels. Several ongoing, randomized controlled trials are underway to examine the impact of these novel agents on ASCVD outcomes. In this comprehensive review, we provide an overview of the biology, epidemiology, and genetics of TGs and ASCVD; we discuss current and novel TG-lowering therapies under development.",
    author = "Sandesara, {Pratik B.} and Virani, {Salim S.} and Sergio Fazio and Michael Shapiro",
    year = "2019",
    month = "1",
    day = "1",
    doi = "10.1210/er.2018-00184",
    language = "English (US)",
    volume = "40",
    pages = "537--557",
    journal = "Endocrine Reviews",
    issn = "0163-769X",
    publisher = "The Endocrine Society",
    number = "2",

    }

    TY - JOUR

    T1 - The forgotten lipids

    T2 - Triglycerides, remnant cholesterol, and atherosclerotic cardiovascular disease risk

    AU - Sandesara, Pratik B.

    AU - Virani, Salim S.

    AU - Fazio, Sergio

    AU - Shapiro, Michael

    PY - 2019/1/1

    Y1 - 2019/1/1

    N2 - Atherosclerotic cardiovascular disease (ASCVD) remains the leading cause of death worldwide. Low-density lipoprotein cholesterol (LDL-C) is a well-established mediator of atherosclerosis and a key target for intervention for the primary and secondary prevention of ASCVD. However, despite substantial reduction in LDL-C, patients continue to have recurrent ASCVD events. Hypertriglyceridemia may be an important contributor of this residual risk. Observational and genetic epidemiological data strongly support a causal role of triglycerides (TGs) and the cholesterol content within triglyceride-rich lipoproteins (TGRLs) and/or remnant cholesterol (RC) in the development of ASCVD. TGRLs are composed of hepatically derived very low-density lipoprotein and intestinally derived chylomicrons. RC is the cholesterol content of all TGRLs and plasma TGs serve as a surrogate measure of TGRLs and RC. Although lifestyle modification remains the cornerstone for management of hypertriglyceridemia, many novel drugs are in development and have shown impressive efficacy in lowering TG levels. Several ongoing, randomized controlled trials are underway to examine the impact of these novel agents on ASCVD outcomes. In this comprehensive review, we provide an overview of the biology, epidemiology, and genetics of TGs and ASCVD; we discuss current and novel TG-lowering therapies under development.

    AB - Atherosclerotic cardiovascular disease (ASCVD) remains the leading cause of death worldwide. Low-density lipoprotein cholesterol (LDL-C) is a well-established mediator of atherosclerosis and a key target for intervention for the primary and secondary prevention of ASCVD. However, despite substantial reduction in LDL-C, patients continue to have recurrent ASCVD events. Hypertriglyceridemia may be an important contributor of this residual risk. Observational and genetic epidemiological data strongly support a causal role of triglycerides (TGs) and the cholesterol content within triglyceride-rich lipoproteins (TGRLs) and/or remnant cholesterol (RC) in the development of ASCVD. TGRLs are composed of hepatically derived very low-density lipoprotein and intestinally derived chylomicrons. RC is the cholesterol content of all TGRLs and plasma TGs serve as a surrogate measure of TGRLs and RC. Although lifestyle modification remains the cornerstone for management of hypertriglyceridemia, many novel drugs are in development and have shown impressive efficacy in lowering TG levels. Several ongoing, randomized controlled trials are underway to examine the impact of these novel agents on ASCVD outcomes. In this comprehensive review, we provide an overview of the biology, epidemiology, and genetics of TGs and ASCVD; we discuss current and novel TG-lowering therapies under development.

    UR - http://www.scopus.com/inward/record.url?scp=85062878812&partnerID=8YFLogxK

    UR - http://www.scopus.com/inward/citedby.url?scp=85062878812&partnerID=8YFLogxK

    U2 - 10.1210/er.2018-00184

    DO - 10.1210/er.2018-00184

    M3 - Review article

    VL - 40

    SP - 537

    EP - 557

    JO - Endocrine Reviews

    JF - Endocrine Reviews

    SN - 0163-769X

    IS - 2

    ER -